Biguanides use at the early stages of insulin resistance syndrome

Objective. To study lipid and carbohydrate metabolism in patients with different types and degree of obesity. Results. Patients with abdominal obesity have more severe atherogenic lipid abnormalities, higher levels of nonesterified fatty acids and decreased tissue insulin sensitivity than patients with gluteofemoral obesity. Lipid parameters did not differ in obese patients with type 2 diabetes and obese non-diabetic patients. Treatment with metformin resulted in weight loss, decrease of waist-to-hip ratio, insulin resistance and hyperinsulinemia, and improvement of lipid profile in non-diabetic patients with abdominal obesity. Conclusion. Our findings show that in patients with abdominal obesity biguanides should be recommended at the stage preceding the development of full metabolic syndrome.

obesity, insulin resistance, dyslipidemia, biguanides

1. Manson J.E., Skerrett P.J., Greenland P. et al. The escalating pandemic of obesity and sedentary lifestyle. A call to action for clinicians // Arch. Intern. Med. - 2004. - Vol. 164, № 3. - P. 249-258. 2.

2.

3. Ожирение / Под ред. Н.А. Белякова и В.И. Мазурова. - СПб.: Издательский дом СПбМАПО, 2003. - 520 с.

4.

5. Дедов И.И. Ожирение: этиология, патогенез, клинически аспекты. 2-е изд. руководство для врачей. - М.: Издательство МИА, 2006. - 456 с.

6.

7. Poirier P., Eskel R.H. The heart and obesity // Hurst' The Heart / Eds. V. Furst, R.W. Alexander, S. King et al. - N.Y.: McGraw-Hill Companies, 2000. - P. 2289-2303.

8.

9. Yusuf S., Hawken S., Ounpuu S. et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study // Lancet. - 2004. - Vol. 364, № 9438. - P. 937-952.

10.

11. Алмазов В.А., Благосклонная Я.В., Шляхто Е.В., Красильникова Е.И. Метаболический сердечно-сосудистый синдром. - Спб.: Изд-во СПбГМУ, 1999. - 208 с. 7.

12.

13. Метаболический синдром. - М.: Изд-во «Пратика», 2011. - 272 с.

14.

15. Беляков Н.А., Сеидова Г.Б., Чубриева С.Ю., Глухов Н.В. Метаболический синдром у женщин (патофизиология и клиника). - СПб.: Издательский дом СПбМАПО, 2005. - 440 с.

16.

17. Шевченко О.П., Праскурничий Е.А., Шевченко А.О. Метаболический синдром. - М., 2004. - 141 с.

18.

19. Красильникова Е.И., Благосклонная Я.В., Быстрова А.А. и др. Метаболический сердечно-сосудистый синдром // Профилактич. и клинич. медицина. - 2010. - № 3-4. - С. 15-26.

20.

21. Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/ National Heart, Lung and Blood Institute Scientific Statement // Circulation. - 2005. - Vol. 112, № 17. - P. 2735-2752. 12.

22.

23. International Diabetes Federation. Worldwide definition of the metabolic syndrome. - 2005. [Электронный ресурс]. URL: http: www/idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf.

24.

25. Stolar M.W <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Stolar%20MW%22%5BAuthor%5D>. Insulin resistance, diabetes, and the adipocyte // Am. J. Health Syst. Pharm. <javascript:AL_get(this,%20'jour',%20'Am%20J%20Health%20Syst%20Pharm.');> - 2002. - Vol. 59, Suppl. 9. - P. S3-8.

26.

27. Reddy K.J <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Reddy%20KJ%22%5BAuthor%5D>., Singh M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Singh%20M%22%5BAuthor%5D>., Bangit J.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bangit%20JR%22%5BAuthor%5D>., Batsell R.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Batsell%20RR%22%5BAuthor%5D>. The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review// J. Cardiovasc. Med. (Hagerstown). <javascript:AL_get(this,%20'jour',%20'J%20Cardiovasc%20Med%20(Hagerstown).');> - 2010. - Vol. 11, № 9. - P. 633-647. 15.

28.

29. Fukushima Y <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Fukushima%20Y%22%5BAuthor%5D>., Urakaze M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Urakaze%20M%22%5BAuthor%5D>., Tobe K <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tobe%20K%22%5BAuthor%5D>. Metabolic syndrome // Nippon Rinsho. <javascript:AL_get(this,%20'jour',%20'Nippon%20Rinsho.');> - 2010. - Vol. 68, № 2. - P. 299-304. 16.

30.

31. Bayturan O <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bayturan%20O%22%5BAuthor%5D>., Tuzcu E.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tuzcu%20EM%22%5BAuthor%5D>., Lavoie A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lavoie%20A%22%5BAuthor%5D>. et al. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis // Arch. Intern. Med. <javascript:AL_get(this,%20'jour',%20'Arch%20Intern%20Med.');> - 2010. - Vol. 170, № 5. - P. 478-484.

32.

33. Nieves D., Retzlaff B., Walden E. et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat // Diabetes. - 2003. - Vol. 52, № 1. - P. 172-179.

34.

35. Благосклонная Я.В., Красильникова Е.И., Шляхто Е.В. Туловищное ожирение и инсулинорезистентность - ключевое звено метаболического сердечно-сосудистого синдрома // Сахарный диабет. - 2003. - № 1. - С. 12-15. 19.

36.

37. Sotornнk R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sotorn%C3%ADk%20R%22%5BAuthor%5D>. Adipose tissue blood flow and metabolic syndrome // Cas. Lek. Cesk. <javascript:AL_get(this,%20'jour',%20'Cas%20Lek%20Cesk.');> - 2010. - Vol. 149, № 4. - P. 155-159.

38.

39. Abdul-Ghani M.A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Abdul-Ghani%20MA%22%5BAuthor%5D>., DeFronzo R.A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22DeFronzo%20RA%22%5BAuthor%5D>. Pathogenesis of insulin resistance in skeletal muscle // J. Biomed. Biotechnol. <javascript:AL_get(this,%20'jour',%20'J%20Biomed%20Biotechnol.');> - 2010. - 2010:476279. Epub 2010 Apr 26. 21.

40.

41. Gaidelines on diabetes, pre-diabetes and cardiovascular diseases: full text // Eur. Heart J. - 2007. - Vol. 9, suppl. - P. 3-74.

42.

43. Kruszynska Y., Olesfsky J., Frias J. Effect of obesity on susceptibility to fatty acid-induced peripheral tissue insulin resistance // Metabolism. - 2003. - Vol. 52, № 2. - P. 233-238.

44.

45. Lam T.K., van de Werve G., Giacca A. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites // Am. J. Physiol. Endocrinol. Metab. - 2003. - Vol. 284. - P. 281-290.

46.

47. Ohnishi H., Saitoh S., Ura N. et al. Relationship between insulin resistance and accumulation of coronary risk factors // Diabetes Obes. Metabol. - 2002. - Vol. 4, № 6. - P. 388-393.

48.

49. Chan D.C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chan%20DC%22%5BAuthor%5D>., Watts G.F <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Watts%20GF%22%5BAuthor%5D>. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies // Expert Opin. Pharmacother. <javascript:AL_get(this,%20'jour',%20'Expert%20Opin%20Pharmacother.');> - 2010. [Epub ahead of print]

50.

51. Мамедов М.Н. Возможно ли применение метформина у больных с метаболическим синдромом без сахарного диабета? <http://www.rmj.ru/articles_4264.htm> // Рус. мед. журн. - 2006. - Т. 14, № 13. - С. 936-941.

52.

53. McCarty M.F. A proposal for the locus of metformin's clinical action: potentiation of the activation of pyruvate kinase by fructose-1,6-diphosphate // Med. Hypoth. - 1999. - Vol. 52, № 3. - P. 89-93.

54.

55. Zimmet P., Collier G. Clinical efficacy of metformin against insulin resistance parameters // Drugs. - 1999. - Vol. 58, suppl. - P. 21-28. 29.

56.

57. Metformin. The gold standard: a scientific handbook / Eds. C.J. Bailey, I.W. Campbell, J.C.N. Chan et al. - Trento: John Wiley & Sons, 2007. - 288 p.

58.

59. Недосугова Л.В. Новые подходы к терапии сахарного диабета 2 типа // Рус. мед. журн. - 2006. - Т. 14, № 13. - С. 3-10.

60.

61. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM // Diabetes. - 1997. - Vol. 46, № 1. - P. 3-10. 32.

62.

63. Tota-Maharaj R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tota-Maharaj%20R%22%5BAuthor%5D>., Defilippis A.P <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Defilippis%20AP%22%5BAuthor%5D>., Blumenthal R.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Blumenthal%20RS%22%5BAuthor%5D>., Blaha M.J <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Blaha%20MJ%22%5BAuthor%5D>. A practical approach to the metabolic syndrome: review of current concepts and management // Curr. Opin. Cardiol. <javascript:AL_get(this,%20'jour',%20'Curr%20Opin%20Cardiol.');> - 2010. - Vol. 22, № 5. - P. 502-512.

64.

65. Large V., Beylot M. Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin // Diabetes. - 1999. - Vol. 48, № 6. - P. 1251-1257.